June 28, 2021
Watch for 1 minute
Source / information
Published by:
Source:
Healio interview
Disclosure:
Wexler reports a relevant financial relationship with Novo Nordisk. Pratley does not report any relevant financial information.
ADD SUBJECT TO EMAIL ALERTS
Receive an email when new articles are published on
Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe
We could not process your request. Please try again later. If this problem persists, please contact customerservice@slackinc.com.
Back to Healio
Exclusive in this video, Richard E. Pratley, MD, talks to Deborah J. Wexler, MD, MSc, on the results and effects of the long-term GRADE study comparing the effectiveness of second-line diabetes drugs in conjunction with metformin.
Pratley is the Samuel E. Crockett Chair in Diabetes Research and Medical Director of the AdventHealth Diabetes Institute, and Wexler is Associate Professor of Medicine at Harvard Medical School, Associate Clinical Director of the MGH Diabetes Unit, and Clinical Director of the MGH Diabetes Center.
GRADE showed that the GLP1 receptor agonist liraglutide and insulin glargine were more effective than the sulphonylurea glimepiride and the sulfonylurea glimepiride and the more than 5,000 participants over an average period of 4 years in more than 5,000 participants DPP4 inhibitor sitagliptin.
Pratley and Wexler discuss the differences in study design between GRADE and other large studies, including more recent cardiovascular outcome studies, the different effects of the drugs on weight and hypoglycemia, and the future of individualized diabetes management.
ADD SUBJECT TO EMAIL ALERTS
Receive an email when new articles are published on
Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe
We could not process your request. Please try again later. If this problem persists, please contact customerservice@slackinc.com.
Back to Healio
